Work

Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer

Year: 2015

Type: review

Abstract: Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.

Source: BioMed Research International

DOI: 10.1155/2015/413076

Authors: Nirmala Chandralega Kampan, Mutsa Tatenda Madondo, Orla M. McNally, Michael Quinn, Magdalena Plebanski

Institutions: Royal Women's Hospital, The Alfred Hospital, Monash University, The University of Melbourne

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,680